77
Participants
Start Date
June 30, 2006
Primary Completion Date
December 31, 2009
Study Completion Date
December 31, 2009
Switch
Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.
Control
Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.
VA San Diego Healthcare System, San Diego
Collaborators (1)
National Institute of Mental Health (NIMH)
NIH
Pfizer
INDUSTRY
Veterans Medical Research Foundation
OTHER